At the forefront of medical advances, this research group is developing innovative strategies to improve the treatment of pancreatic cancer. The lethality of this cancer stems from its heterogeneity: pancreatic carcinoma does not present itself as a uniform clinical entity, but rather in various molecular subtypes, each requiring a targeted therapeutic approach. A primary focus of our research lies in the investigation of interactions that are specific to molecular subtypes between cancer cells and other components in the tumor microenvironment. Particularly, the role of integrins is a key area of interest in this context. Additionally, our team is directed towards developing serum protein markers that can accurately identify the molecular subtype of pancreatic cancer. We are also pioneers of a series of perioperative strategies for the care of patients undergoing high-risk, major pancreatic resections.